Breaking News
1 day ago
Simantini Singh Deo

Revagenix doses first participant in Phase 1 trial of Rev-56 for non-cystic fibrosis bronchiectasis.
Simantini Singh Deo

Cato Healthcare Supply appoints Ryan F. Zackon as President and Chief Executive Officer.
Simantini Singh Deo

Medicus Pharma receives FDA clearance to launch registrational Phase 2b SkinJect trial for Gorlin Syndrome.
Simantini Singh Deo

Lexicon Pharmaceuticals completes patient enrollment in pivotal Phase 3 SONATA-HCM trial.
Simantini Singh Deo
